S-1/A: Alpha Cognition Files Amendment No. 3 to Form S-1 Registration Statement, Eyes Potential Public Offering

Alpha Cognition Inc. files an amendment to its S-1 registration statement, paving the way for a potential public offering and resale of common shares by selling stockholders.

Summary

• Alpha Cognition Inc. has filed Amendment No. 3 to its Form S-1 registration statement with the SEC.
• The filing relates to the offering and resale of up to 42,676,511 common shares by selling stockholders who acquired these shares through private placements between August 2023 and January 2024.
• Alpha Cognition will not receive any proceeds from the sale of these shares.
• The company's lead drug candidate, ALPHA-1062, is under FDA review for the treatment of mild-to-moderate Alzheimer's disease, with a PDUFA goal date of July 27th, 2024.
• Alpha Cognition is also pursuing the out-licensing of its TBI indication to Alpha Seven Therapeutics Inc.
• The company is an emerging growth company and a smaller reporting company, allowing it to comply with reduced public company reporting requirements.
• The company's common shares are traded on the CSE under the symbol ACOG and on the OTCQB under the symbol ACOGF.
• The last reported sale price of Alpha Cognition's common shares on the CSE was C$0.70 on May 21, 2024.
• The last quoted price of Alpha Cognition's common shares on the OTCQB was $0.5330 on May 21, 2024.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The potential for ALPHA-1062 and the out-licensing agreement are positive, but the company's financial situation and the risks associated with drug development temper the overall sentiment.

Positives

• FDA acceptance of the NDA for ALPHA-1062 with a PDUFA goal date of July 27, 2024.
• Potential out-licensing of the TBI indication of ALPHA-1062 to Alpha Seven Therapeutics Inc.
• Filing of a new composition-of-matter patent that secures broad protection for ALPHA-1062 into 2044 if approved.
• Completion of the fifth and final closing of the Q2 2023 PP, raising gross proceeds of $8.45 million.

Negatives

• The company will not receive any proceeds from the sale of common shares by the selling stockholders.
• The company has incurred significant net losses since inception and expects to continue to incur significant expenses and operating losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.
• The company's stock price may be volatile, and investors may not be able to resell common shares at or above the price they paid.
• An active, liquid, and orderly market for the company's common shares may not develop.

Risks

• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of ALPHA-1062 and any future product candidates.
• The company may encounter substantial delays in its preclinical studies and clinical trials or may not be able to conduct or complete its preclinical studies or clinical trials on the timelines it expects, if at all.
• Use of the company's therapeutic candidates could be associated with side effects, adverse events, or other properties or safety risks.
• The company faces significant competition in an environment of rapid technological and scientific change.
• The successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies.
• The company relies on third-party suppliers to manufacture its product candidates, and the loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide the company with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect the company's business, financial condition, results of operations and prospects.
• The company's success depends on its ability to obtain and maintain patent protection for its technology and product candidates including its lead product candidate, ALPHA-1062.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.
• The company will need to increase the size of its organization, and it may experience difficulties in managing growth.
• If the company fails to attract and retain senior management and key scientific personnel, its business may be materially and adversely affected.
• Unfavorable global economic or political conditions could adversely affect the company's business, financial condition or results of operations.
• The company will incur significant costs as a result of operating as a public company, and its management will devote substantial time to new compliance initiatives.

Future Outlook

The company plans to continue advancing its development and commercialization activities for ALPHA-1062 in mild-to-moderate Alzheimers disease and pursue the out-licensing of its TBI indication to Alpha Seven, where the TBI indication can be further developed.

Industry Context

The document highlights the limited treatment options available for neurodegenerative diseases like Alzheimer's, emphasizing the need for new therapies. It also acknowledges the competitive landscape and the challenges in developing and commercializing new drugs in this field.

Comparison to Industry Standards

• The document mentions Biogen's Aduhelm and Corium's Adlarity as recent FDA approvals in the Alzheimer's space, indicating the competitive landscape.
• It also references generic competitors like donepezil, rivastigmine, galantamine, and memantine, highlighting the existing market standards.
• The document notes that many providers and caregivers believe the approved generic medications provide limited efficacy and adverse effects, suggesting a potential market opportunity for ALPHA-1062 if it can demonstrate improved efficacy and tolerability.

Stakeholder Impact

• Shareholders: Potential for increased value if ALPHA-1062 is approved and successfully commercialized, but also risk of dilution from future equity offerings.
• Employees: Job security and potential for career advancement if the company is successful.
• Patients: Potential access to a new treatment option for Alzheimer's disease.
• Suppliers: Potential for increased business if ALPHA-1062 is successfully commercialized.

Next Steps

• Respond to regulatory questions and inquiries from FDA in a satisfactory manner and negotiate the commercial label and approval of the product with FDA, which is anticipated in Q3 2024.
• Continue its development activities and commercialization preparations around ALPHA-1062.
• Complete the out-license the TBI asset into Alpha Seven where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

ALPHA-1062, Alzheimers disease, Registration statement, Common shares, FDA, Biopharmaceutical, Clinical trials, Neurodegenerative diseases, Private placement, Emerging growth company, Smaller reporting company, Alpha Cognition